Huntington National Bank’s Lineage Cell Therapeutics LCTX Stock Holding History

Huntington National Bank’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-229	Closed	–	–	1762
2018 Q3	$0	Hold	229	–	–	﹤0.01%	1774
2018 Q2	$0	Hold	229	–	–	﹤0.01%	1609
2018 Q1	$0	Hold	229	–	–	﹤0.01%	1630
2017 Q4	$0	Hold	229	–	–	﹤0.01%	1666
2017 Q3	$0	Hold	229	–	–	﹤0.01%	1629
2017 Q2	$0	Hold	229	–	–	﹤0.01%	1543
2017 Q1	$0	Hold	229	–	–	﹤0.01%	1428
2016 Q4	$0	Hold	229	–	–	﹤0.01%	1472
2016 Q3	$0	Hold	229	–	–	﹤0.01%	1554
2016 Q2	$0	Hold	229	–	–	﹤0.01%	1597
2016 Q1	$0	Sell	229 -19	-8%	-$42	﹤0.01%	1774
2015 Q4	$0	Hold	248	–	–	﹤0.01%	1666
2015 Q3	$0	Hold	248	–	–	﹤0.01%	1759
2015 Q2	$0	Hold	248	–	–	﹤0.01%	1798
2015 Q1	$0	Hold	248	–	–	﹤0.01%	1747
2014 Q4	$0	Buy	+248	New	+$671	﹤0.01%	1744
2014 Q1	–	Sell	-248	Closed	–	–	1362
2013 Q4	$0	Hold	248	–	–	﹤0.01%	1729
2013 Q3	$0	Hold	248	–	–	﹤0.01%	1761
2013 Q2	$0	Buy	+248	New	+$794	﹤0.01%	1731

Other funds holding LCTX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

IndexIQ Advisors New York $2.82B AUM 12.48% 1-Year Est. Return

Huntington National Bank's LCTX Position: Q4 2018 in Review

Huntington National Bank sold out of Lineage Cell Therapeutics (LCTX) in Q4 2018, closing a stake of 229 shares.

Huntington National Bank first reported a position in LCTX in Q2 2013 and held it in 19 quarters. The position peaked at $0 in Q3 2018. 105 funds tracked by Wall St. Rank hold LCTX as of Q4 2018.

Huntington National Bank reported no remaining Lineage Cell Therapeutics position as of Q4 2018 after selling out during the quarter.
Huntington National Bank sold 229 Lineage Cell Therapeutics shares in Q4 2018.
Huntington National Bank first reported a position in Lineage Cell Therapeutics in Q2 2013 and held it in 19 quarters.
Huntington National Bank's Lineage Cell Therapeutics position peaked at $0 in Q3 2018.
105 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2018.

Based on Huntington National Bank's 13F filing for Q4 2018, filed 28 Jan 2019.